SecBot SecBot
6-K ·Filed May 18, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001654954-26-005044
Notable filing: 6-K
Actionable Insight ▲ Bullish

FDA approval of a first-in-class hypertension drug with strong Phase III data is a clear positive catalyst for AZN. Monitor initial prescription trends, pricing/reimbursement decisions, and upcoming Phase III readouts in CKD and heart failure for further upside.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$183.91
T+0 close · May 18, 2026 · via day close
Latest settled
−14.01%
T+60 · $158.14
Vs SPY
−18.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $183.91entry
  2. T+1 · 6mo ago +0.42%α +1.07% · $184.68
  3. T+5 · 6mo ago +1.74%α +0.12% · $187.11
  4. T+20 · 5mo ago −3.61%α −5.80% · $177.27
  5. T+60 · 3mo ago −14.01%α −18.59% · $158.14

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca announced FDA approval of Baxfendy (baxdrostat), a first-in-class aldosterone synthase inhibitor for adults with uncontrolled or resistant hypertension. The approval, based on the Phase III BaxHTN trial showing a 9.8 mmHg placebo-adjusted systolic blood pressure reduction at the 2mg dose, opens a new treatment option for ~23 million US patients uncontrolled on two or more medications. This is a significant pipeline milestone for AstraZeneca's CVRM franchise, though the financial impact will depend on commercial execution and pricing.

Key Facts

  • FDA approved Baxfendy (baxdrostat) as first-in-class aldosterone synthase inhibitor for hypertension in adults not adequately controlled on current medications.
  • Approval based on BaxHTN Phase III trial: 2mg dose showed 15.7 mmHg absolute SBP reduction from baseline, 9.8 mmHg placebo-adjusted (p<0.001).
  • ~23 million US patients have uncontrolled hypertension despite two or more antihypertensive medications.
  • Baxfendy is also being investigated in Phase III trials for primary aldosteronism, chronic kidney disease (with dapagliflozin), and heart failure prevention.
  • AstraZeneca acquired Baxfendy via CinCor Pharma acquisition in February 2023.

Financial Impact

First-in-class approval in a large addressable market (~23M US patients uncontrolled on ≥2 meds); peak sales potential is significant but not quantified in the filing.

revenuepipeline value

Risk Factors

  • Commercial uptake may be slower than expected due to pricing pressure or payer restrictions.
  • Safety signals in broader post-market use could emerge, though Phase III data showed no unanticipated findings.
  • Competition from existing antihypertensives and other pipeline ASI candidates could limit market share.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-005044
Document: 0001654954-26-005044-index-headers.html0001654954-26-005044
Document: 0001654954-26-005044-index.html0001654954-26-005044
Document: 0001654954-26-005044.txt0001654954-26-005044

Track record

77 reports on AZN

Performance horizon

18 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (11h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026